Kura Oncology is a biotechnology business based in the US. Kura Oncology shares (KURA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.43 – an increase of 8.98% over the previous week. Kura Oncology employs 192 staff and has a trailing 12-month revenue of around $53.9 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $6.43 |
|---|---|
| 52-week range | $5.41 - $23.48 |
| 50-day moving average | $7.03 |
| 200-day moving average | $13.36 |
| Wall St. target price | $28.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.02 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.43 from 2025-04-25
| 1 week (2025-04-17) | 8.98% |
|---|---|
| 1 month (2025-03-28) | -8.79% |
| 3 months (2025-01-28) | -17.25% |
| 6 months (2024-10-28) | -63.73% |
| 1 year (2024-04-26) | -67.28% |
|---|---|
| 2 years (2023-04-27) | -33.16% |
| 3 years (2022-04-27) | 14.26 |
| 5 years (2020-04-27) | 10.42 |
| Revenue TTM | $53.9 million |
|---|---|
| Gross profit TTM | $-101,464,000 |
| Return on assets TTM | -19.97% |
| Return on equity TTM | -42.91% |
| Profit margin | 0% |
| Book value | $5.29 |
| Market Capitalization | $519.4 million |
TTM: trailing 12 months
We're not expecting Kura Oncology to pay a dividend over the next 12 months.
Over the last 12 months, Kura Oncology's shares have ranged in value from as little as $5.41 up to $23.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kura Oncology's is 0.824. This would suggest that Kura Oncology's shares are less volatile than average (for this exchange).
Kura Oncology, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co. , Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.